Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0446)

Madrid 28040

0 studies enrolling now · 1 studies all time

What they study most

Hematological Malignancies

Studies at this site

• A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) — Completed